Evaluating Orally Administered Meloxicam-Loaded Polymeric Nanocapsules in Female Dogs: A Population Pharmacokinetic Modeling Study
Pharmaceuticals · 03.03.2026 · 19 (3) · 412
DOI: 10.3390/ph19030412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 03.03.2026. Verfasst von Flávia Elizabete Guerra Teixeira und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Pharmacometric Laboratory, LABFAR, Federal University of Pampa (UNIPAMPA), Uruguaiana 97501-970, RS, Brazil. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, National Institute of Science and Technology of Drugs and Medicines, Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul.
Abstract (Originalsprache)
Background/Objectives: Meloxicam (MLX) is a nonsteroidal anti-inflammatory drug (NSAID) recommended for treating acute and chronic pain in dogs, frequently administered prophylactically to mitigate postoperative pain; however, its utility is limited by characteristic NSAID-associated adverse effects, such as gastrointestinal side effects. Nanosystems offer the potential to minimize adverse effects by sustaining drug release. Therefore, this study assessed the pharmacokinetics of MLX nanoencapsulation in female dogs undergoing ovariohysterectomy using a population pharmacokinetic (PopPK) modeling approach.
Methods
MLX-loaded polymeric nanocapsules (NC-MLX) were prepared using the nanoprecipitation method and characterized by zeta potential, pH, mean diameter, particle size distribution, and drug content. Dogs received 0.2 mg/kg of either NC-MLX or free MLX orally, 4 h before surgery, and plasma samples were analyzed using an HPLC-PDA method. Pharmacokinetics were characterized by non-compartmental analysis and PopPK modeling. Several compartmental structures, variability models, and residual error models were explored, and relevant covariates were investigated.
Results
NC-MLX had an average diameter of 326 ± 13 nm, a zeta potential of −26.2 ± 6.4 mV, and drug loading of 99.47% ± 0.01%. NC-MLX showed a significant increase in the t1/2 (36.99 ± 17.26 h) of MLX compared to the free drug (15.22 ± 4.4 h). The best-fitting PopPK model was a two-compartment model with double extravascular first-order absorption rate constants (Ka1 and Ka2), including a lag time for Ka2 and linear elimination, describing the second peak observed in several animals. The nanoformulation was a significant covariate for Tlag2, delaying the time for absorption (1.22 and 2.55 h for free MLX and NC-MLX, respectively) and increasing V2 (0.134 and 0.402 L/kg for free MLX and NC-MLX, respectively). External model validation showed that the final PopPK model accurately predicted plasma concentrations, with MPE% and RMSE values below 15%.
Conclusions
Our findings suggest that NC-MLX alters MLX absorption and distribution profiles, supporting its potential as an alternative for postoperative pain management in dogs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacology and Pharmacometric Laboratory, LABFAR, Federal University of Pampa (UNIPAMPA), Uruguaiana 97501-970, RS, Brazil.
- Pharmaceutical Sciences Post Graduate Program, Federal University of Pampa (UNIPAMPA), Uruguaiana 97501-970, RS, Brazil.
- Animal Science Post Graduate Program, Federal University of Pampa (UNIPAMPA), Uruguaiana 97501-970, RS, Brazil.
ORCID-Profile: Flávia Elizabete Guerra Teixeira, Graziela de Araújo Lock, Camila de Oliveira Pacheco, Tamara Ramos Maciel, Ana Pozzato Funghetto-Ribeiro, Diego Vilibaldo Beckmann, Marília Teresa de Oliveira, Sandra Elisa Haas
Förderung
- National Council for Scientific and Technological Development
- National Institute of Science and Technology of Drugs and Medicines
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- Federal University of Pampa
- CAPES
- FAPERGS
- CNPq
- INCT-Inofar
Zitieren
APA
Teixeira, F. E. G., Lock, G. A., Giacomeli, R., Pacheco, C. O., Maciel, T. R., Pozzato Funghetto-Ribeiro, A., Lugoch, G., Beckmann, D. V., Oliveira, M. T., & Haas, S. E. (2026). Evaluating Orally Administered Meloxicam-Loaded Polymeric Nanocapsules in Female Dogs: A Population Pharmacokinetic Modeling Study. Pharmaceuticals, 19(3), 412. https://doi.org/10.3390/ph19030412
Vancouver
Teixeira FEG, Lock GA, Giacomeli R, Pacheco CO, Maciel TR, Pozzato Funghetto-Ribeiro A, et al. Evaluating Orally Administered Meloxicam-Loaded Polymeric Nanocapsules in Female Dogs: A Population Pharmacokinetic Modeling Study. Pharmaceuticals. 2026;19(3):412. doi:10.3390/ph19030412
BibTeX
@article{Teixeira2026,
author = {Teixeira, Flávia Elizabete Guerra and Lock, Graziela de Araújo and Giacomeli, Renata and Pacheco, Camila de Oliveira and Maciel, Tamara Ramos and Pozzato Funghetto-Ribeiro, Ana and Lugoch, Gabriela and Beckmann, Diego Vilibaldo and Oliveira, Marília Teresa de and Haas, Sandra Elisa},
title = {Evaluating Orally Administered Meloxicam-Loaded Polymeric Nanocapsules in Female Dogs: A Population Pharmacokinetic Modeling Study},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {3},
pages = {412},
doi = {10.3390/ph19030412}
}
EUVIMED